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A B S T R A C T
Purpose: Temporal lobe epilepsy with antibodies (abs) against the glutamic acid decarboxylase
65 isoform (GAD-TLE) is known as an immune-mediated neurological syndrome. Here we evaluate the
therapy response to various immunotherapies and epilepsy surgery in this syndrome.
Method: All patients with GAD-TLE and follow-up data and stored serum and CSF samples, identiﬁed and
treated at the Bonn centre from 2002 to 2010, were studied retrospectively. Seizure freedom for 1 year
and reduction of 50%, i.e. therapy response, were assessed. GAD-ab titres and neuropsychological
performances were documented prior and after individual interventions.
Results: Thirteen patients with GAD-TLE were identiﬁed with the following seizure responses:
corticosteroids (5 responders out of 11 treated patients); i.v. immunoglobulins (1/5), apheresis therapy
(1/8); and natalizumab (1/1), selective amygdala-hippocampectomy (2/3). None of the patients achieved
sustained seizure freedom apart from one patient. This patient was on antiepileptic drug treatment after
discontinuation of immunotherapy.
Conclusion: The seizure response to immunotherapies in patients with GAD-TLE was poor. Corticoste-
roids were the most effective regarding seizure response. Especially the poor effects of apheresis
therapies support the idea that GAD-abs are not directly pathogenic. None of three patients was seizure-
free after temporal lobe surgery suggesting that GAD-TLE patients respond worse than others to this type
of intervention. Our results reﬂect the chronic course of the disease with low likelihood for patients with
GAD-TLE to attain long-term seizure freedom.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Glutamic acid decarboxylase (GAD) catalyzes the synthesis of
gamma aminobutyric acid (GABA), the major inhibitory neuro-
transmitter in the central nervous system. Antibodies (abs) against
the GAD65 isoform are markers for insulin dependent diabetes
mellitus and – if present at high titres – immune-mediated§ One of the authors of this paper is a member of the current editorial team of
Seizure. The supervision of the independent peer review process was undertaken
and the decision about the publication of this manuscript were made by other
members of the editorial team.
* Corresponding author at: University Hospital Cologne, Department of
Neurology, Kerpener Straße 62, 50937 Cologne, Germany. Tel.: +49 221 478 4015.
E-mail address: michael.malter@gmx.de (M.P. Malter).
1 All authors have contributed substantially to the ﬁnal version.
http://dx.doi.org/10.1016/j.seizure.2015.05.017
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reneurological syndromes such as stiff-person-syndrome [1], cere-
bellar ataxia [2], as well as limbic encephalitis (LE) and temporal
lobe epilepsy (TLE) in adults [3–5] and children [6,7]. ‘‘Subacute’’
LE with GAD-abs and ‘‘chronic’’ TLE with GAD-abs have been
suggested to be two ends of one spectrum of an immune-mediated
mediotemporal lobe disorder. A plausible explanation for these
two ‘‘poles’’ is that in early stages the condition appears as ‘‘LE’’
and later on as chronic epilepsy [8]. To overcome terminological
inconsistencies, here we use the term ‘‘immune-mediated
temporal lobe epilepsy with GAD-abs’’ (GAD-TLE) irrespective of
disease duration and ‘‘acuity’’. Symptoms consist of temporal lobe
seizures, memory and mood disturbances.
In our former publications [5,9], patients with GAD-TLE had a
worse outcome than patients with abs against the voltage gated
potassium channel (VGKC) complex despite similar immunother-
apeutic interventions (usually monthly i.v.-methylprednisoloneserved.
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Because none of the patients with GAD-TLE became seizure-free, a
more chronic course of the disease has been suggested. Further-
more, direct pathogenicity of GAD-abs is still discussed controver-
sially [10–12]. One would expect that in case of direct involvement
of GAD-abs in pathogenic processes, their reduction should prompt
clinical improvement.
Here, we report retrospectively our single centre experience in
treatment of GAD-TLE. The patients reported here have been
treated a few years after the ﬁrst publications of the good
treatability of encephalitides with abs against the VGKC-complex
[13] or the N-methyl-D-aspartate receptor (NMDAR) [14]. There
was a great optimism that any ab associated autoimmune
encephalitis – including those with GAD-abs – would respond
to adequate and consequent immunological therapy. Here we
evaluate the therapy response to various immunotherapies and
epilepsy surgery in patients with GAD-TLE regarding seizure
frequency reduction and, if available, memory outcome.
2. Methods
2.1. Study cohort
All patients with GAD-TLE with available follow-up data and
with stored serum and CSF samples for ab re-testing, studied from
2002 to 2010 at the University of Bonn, Department of
Epileptology, were included in this retrospective report. The
diagnosis was based on clinical features of seizures of temporal
semiology and evidence of high titre serum GAD-abs (>1:2000 in
accordance with a previous suggestion [15]).
The ab diagnosis was made by use of indirect immunohis-
tochemistry with conﬁrmation through radioimmunoprecipita-
tion (done by Angela Vincent, Oxford/UK). Abs against the other
antigens available for routine testing at that time, i.e. against the
VGKC complex, against the NMDAR and against onconeural
antigens Hu, Ma, amphiphysin, CV2/CRMP5 were excluded. All
available serum and CSF samples were re-tested for this study by
cell-based assays with acetone ﬁxed HEK cells transfected with
GAD65 (Euroimmun, Luebeck/Germany, performed by CGB). The
protocol for indirect immunoﬂuorescence follows the recommen-
dations given by Euroimmun (FA 112d-1005-1, IgG) with few
modiﬁcations: the buffer was PBS (Euroimmun: PBS-Tween); the
secondary system consisted of a goat-anti-human IgG (heavy and
light chain) ab conjugated with DyLight 594 produced by Jackson
ImmunoResearch, West Grove, PA, USA, Code No. 109-515-088 at a
dilution of 1:100 (Euroimmun: goat-anti-human IgG, conjugated
with ﬂuorescein, no further information given); nuclear counter-
staining with Hoechst 33342 at 1:10,000 (Euroimmun: no nuclear
staining); embedding with 1,4-diazabicyclo[2.2.2]octan (Euroim-
mun: glycerol). The stained cells are examined using a ﬂuorescence
microscope (Leica DM 2000; Wetzlar, Germany) with excitation at
592 nm and emission ﬁlter at 616 nm for bound ab and 350/
462 nm for the nuclear counterstain. An endpoint titration was
done by serial dilutions in a multiple of 1:2. The titre is the
concentration at which a signal is just still detectable in
comparison with adjacently stained non-transfected cells. Each
titration is rated by two independent investigators. If the ratings
are divergent, the mean of the two ratings is recorded. The
antibody index (AI, i.e., the ratio between the CSF/serum quotients
of GAD-ab titres and total IgG concentrations) indicates whether
antibodies are produced intrathecally. We took an AI > 4 as an
indication of intrathecal production of the speciﬁc antibody [16].
Clinical and paraclinical data were obtained from the patient
records. Comorbidities were evaluated both at visit 1 and last
follow-up. Tumour searches were performed in all patients
according to a dedicated protocol at visit 1 [17]. For brain MRIs,a dedicated epilepsy protocol [18] was used on a 3 Tesla scanner,
Philips, The Netherlands (Dept. of Neuroradiology) or a 3 Tesla
‘‘Trio’’ scanner from Siemens, Erlangen, Germany (Life&Brain
Institute). If available previous brain MRIs from other institutions
were re-assessed. MRI courses were observed at visit 1 and at last
available follow up to reveal changes on long-term follow up,
especially newly developed hippocampal atrophies. All images
were re-evaluated for this study.
Eight patients were part of our previous study [5], except from
one all with extended follow-up data in the present study. Some
patients were included in the study by Wagner, dealing with
morphological changes on MRI without clinical data reported [19].
2.2. Therapeutic interventions
Most patients received multiple therapeutic interventions in
different chronological sequences. All patients were on antiepileptic
drugs, immunotherapeutic interventions and epilepsy surgery were
added on this. Only one intervention was delivered in an individual
patient at the same time. We analyzed the outcome of each single
therapeutic intervention (regardless of the chronological order of
administration in the individual patient) and grouped them as
follows: corticosteroids, intravenous immunoglobulins (IVIG), aphe-
resis techniques (plasma exchange or immunoadsorption), natali-
zumab, epilepsy surgery. Some patients received temporarily only
antiepileptic drugs (AED) without any other intervention, therapy
response in these periods were observed as well. Azathioprine (Aza)
and mycophenolat-mofetil (MMF) were given as oral long-term
immunosuppressants in some patientssubsequentto immunothera-
pies or epilepsy surgery. Their use was considered as supportive
treatment and not included in further analysis.
2.3. Immunotherapy regimens
Immunotherapies were delivered as off-label individual treat-
ment attempts after obtaining informed patient consent (compas-
sionate use).
2.3.1. Corticosteroids
They were given as monthly i.v.-methylprednisolone (MP)
pulses (500–1000 mg/day on 3–5 consecutive days) or continu-
ously per os with initial standard doses of 100 mg/day. The decision
on therapy duration and long-term dosage was made individually.
To characterize the ‘‘intensity’’ of each intervention, corticosteroid
doses were expressed as MP-equivalent doses (prednisone or
prednisolone doses were multiplied by 0.8 [20]).
2.3.2. IVIG
IVIG were given at doses of 0.4/kg body-weight/day. They were
delivered in monthly pulses, initially starting with sequences of
three to ﬁve doses on consecutive days and thereafter monthly
single day pulses in the following. Total doses were calculated to
characterize the ‘‘intensity’’ of each intervention.
2.3.3. Apheresis therapy
This was performed as plasmapheresis or immunoadsorption
according to commonly accepted principles. In four patients
immunoadsorption was combined with continuous lumbar CSF
drainage over 4 days with maximal drain of 150 ml/day (a
simpliﬁed version of Wollinsky’s liquorpheresis or CSF-ﬁltration
[21,22]) based on the assumption that a removal of the ab-
containing CSF could reduce ab load in the CNS.
2.3.4. Natalizumab
It was used similar to the therapy regimen in multiple sclerosis
with monthly single day infusions of 300 mg i.v. Before initiation of
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3 months before and infectious causes were re-evaluated exten-
sively in serum and CSF. Infusions were given on an in-patient basis.
2.4. AED
AED treatment was administered in all patients according to
generally clinically accepted principles at the discretion of the
treating physician to achieve maximum seizure control and
tolerability. Changes were made in cases of intolerabilities or lack
of effectiveness. Some patients received only AEDs for a period
because efﬁcacy of immunotherapy was assumed low and was
discontinued therefore.
2.5. Epilepsy surgery
Selective amygdalo-hippocampectomy was offered to selected
drug-resistant patients after comprehensive presurgical diagnos-
tics according to generally accepted standards [23].
2.6. Outcome parameter
In each patient, periods with the above tabulated therapeutic
interventions were retrospectively deﬁned from the patient
records. Outcome variables were seizure frequency and, where
available, memory outcome and ab titre changes.
2.6.1. Seizure frequency
The number of all documented seizures in the month prior and
after a therapeutic intervention was taken from patient diaries or –
if unavailable – from frequency estimates of the patients and their
relatives. Seizure frequency reduction of 50% was considered as
treatment response. Seizure freedom was rated as completely
seizure-free including auras (Engel class IA [24]) for at least
12 months [25].
2.6.2. Memory performance
Neuropsychological testing was performed at timepoints prior
to and after immunological interventions. Tests regularly com-
prised memory capacities indicative of temporal lobe functions. For
verbal memory (VM) capacities the Verbal Learning and Memory
Test (a German adaptation of the Rey Auditory Verbal Learning Test
[26]) and for ﬁgural memory (FM) assessment the Diagnostikum fu¨r
Cerebralscha¨digung, revised version [27], were used. To condense
the information from these tests, data were transformed into a
single summary score representative for the respective memory
domain as described in detail before [5]. A performance below one
standard deviation (SD) of normal controls was classiﬁed as
abnormal. For follow-up ratings, individual changes in performance
were categorized using reliable change indices according to
previous proposals. Relevant improvement was classiﬁed as change
from abnormal to normal values. Deterioration was deﬁned as
change from normal to abnormal capacities.
2.7. Statistics
For numerical data in memory tests before and after an
intervention, a paired-t-test was used. P-values < 0.05 (two-tailed)
were considered as signiﬁcant.
3. Results
3.1. Visit 1
Thirteen patients were identiﬁed. For individual patient
characteristics see Table 1. Most of the patients (85%) werefemales with a median age at disease onset of 24 years (range: 8–
47) and median disease duration of 18 months (range 1–252). All
patients had clinical seizures (median: 10/month, range 1–150).
Memory functions were impaired in the majority of patients (77%),
often in both domains (46%). Only three patients, however, were in
the range less than 1 standard deviation of normal controls, i.e.,
most were impaired, but not severely. MRI features revealing
mediotemporal T2/FLAIR signal increase and swelling compatible
with limbic encephalitis were observed in all patients with GAD-
TLE at visit 1 or in previous MRIs. MRI abnormalities were
unilateral (85%) or bilateral (15%). In two patients selective
amygdalo-hippocampectomy was performed prior to the diagno-
sis of GAD-abs and prior to visit 1 (details are given below, Section
3.3). One patient had right sided swelling and left-sided
hippocampal atrophy at visit 1. In this patient, previous MRIs
were congruent with a left-sided encephalitic mediotemporal
onset before atrophy. Additional bilateral hyperintense lesions
outside the mediotemporal structures were seen in three patients:
in thalamus and insula, in the depth of cortical sulci and around the
fourth ventricle. Serum titres ranged from 1:2000 to 1:64,000, CSF
titres from 1:16 to 1:1000. Abs were synthesized intrathecally in
77% of the patients.
3.2. Response to individual therapeutic interventions
3.2.1. Immunotherapies (N = 13)
An overview of the performed therapy regimens and their
chronological sequences in individual patients is given in
Fig. 1. Concomitant AED treatment was conducted in all patients.
MP pulses were the most frequent applied immunotherapy (77%),
in 62% as ﬁrst immunotherapy.
3.2.1.1. Corticosteroids (N = 11). The corticosteroid interventions
lasted for a median of 4 months (1–7 months). The median total
dose was 19 g methylprednisolone equivalent (3–30 g). Five
patients (45%) responded to corticosteroid therapy. One patient
gained short-time seizure-freedom for one month, but treatment
had to be changed due to relevant hyperglycaemia. Subsequently,
this patient developed insulin dependent diabetes mellitus.
Neuropsychologically, there was no group effect for memory
changes under therapy (t-test pre vs. post, N = 7). On an individual
level improvement was only seen for FM in one patient, whereas
deterioration in FM was seen in another patient as well. Serum
titres changed by a median of 50% (88% to 0%; N = 5), CSF titres
remained stable in two patients and went down by 88% in one
patient. Notably, adverse events were observed in six patients
(55%): Cushing syndrome in three patients (50%), hyperglycaemia
(evolving into diabetes mellitus, probably GAD ab related), sleep
disorders, nervousness and psychosis in one patient each.
3.2.1.2. IVIG (N = 5). This intervention was performed for a median
of 3 months (2–5 months). The patients received a median total
dose of 3 g/kg body weight (range 3–4 g). A seizure response was
only observed in one patient (20%). Again, memory changes (N = 3)
were without group effect (t-test: n.s.) and one patient deteriorat-
ed in FM on an individual level. GAD-ab titres changed by 50%
and 0% where tested; CSF titres changed in the respective patients
by 0% and +300%. Treatment was well tolerated in all cases.
3.2.1.3. Apheresis therapy (N = 8). Eight patients underwent immu-
noadsorption. Three out of eight patients underwent one or two
sequences of 9, 10 and 20 plasmapheresis sessions before (median
duration 1 months, range 1–2 months). This had no effect on
seizure frequency. Hence, therapy was switched to immunoad-
sorption in these three cases. Immunoadsorption was performed
as sequence of 16 sessions in median (range: 11–26) each (median
T
a
b
le
1
In
d
iv
id
u
a
l
p
a
ti
e
n
t
ch
a
ra
ct
e
ri
st
ic
s
a
t
v
is
it
1
a
n
d
fo
ll
o
w
u
p
in
G
A
D
-T
LE
p
a
ti
e
n
ts
.
V
is
it
1
G
e
n
d
e
r/
a
g
e
a
t
o
n
se
t
(y
e
a
rs
)
D
is
e
a
se
d
u
ra
ti
o
n
(m
o
)
N
o
o
f
sz
/m
o
M
e
m
o
ry
d
e
ﬁ
ci
ts
M
R
I
sw
e
ll
in
g
M
R
I
a
tr
o
p
h
y
A
E
D
C
o
-
m
o
rb
id
.
FU p
e
ri
o
d
(m
o
n
th
)
M
a
in
IT
a
S
u
p
p
o
rt
iv
e
IT
S
A
H
N
o
.
o
f
sz
/m
o
M
e
m
o
ry
d
e
ﬁ
ci
ts
A
b
ti
tr
e
s
se
ru
m
A
b
ti
tr
e
s
C
S
F
M
R
I
sw
e
ll
in
g
M
R
I
a
tr
o
p
h
y
A
E
D
C
o
-m
o
rb
id
.
1
F,
2
3
1
0
8
V
M
,
FM
L
S
A
H
R
1

8
4
M
P
,
IV
IG
A
za
R
2
V
M
,
FM
+
+
L
S
A
H
R
4

2
F,
4
7
2
1
1
2
V
M
,
FM
R
L

1

4
0
M
P
,
P
E
X
,
IA
,
C
y
c,
M
M
F

2
V
M
+
+
L

2
ID
D
M
,
S
LS
3
F,
2
4
1
6
8
V
M
L

2

1
2
M
P


0
.2
V
M
,
FM
+
n
.d
.
N

2

4
F,
1
8
1
1
V
M
,
FM
R

1

3
4
M
P
,
IA
C
y
c,
M
M
F

0
V
M
,
FM
+
n
.d
.
R
L

2

5
F,
2
0
4
0
1
5
0

R
L

1

5
5
M
P


3
0

+
n
.d
.
R
L

3

6
F,
2
1
5
4
1
0

R
L
2
S
LS
3
9
IV
IG
,
IA
,
C
y
c,
M
M
F

5

+
n
.d
.
R
L
3
S
LS
7
M
,
2
6
4
1
3
5

L

0
ID
D
M
3
9
M
P


3
0

+
L

2
ID
D
M
8
F,
1
7
1
8
3
0
FM
R

2

5
1
M
P
,
IV
IG
,
IA
,
N
a
ta
M
M
F

5

+

R

2

9
F,
4
3
8
6
FM
L

1

2
6
P
E
X
,
IA
C
y
c

8

+
+
R
L

2

1
0
F,
8
2
5
2
3
V
M
,
FM
R
S
A
H
L
3

3
7
M
P
,
IV
IG
,
P
E
X
,
IA
C
y
c,
A
za
L
2
0
V
M
+
+
R
S
A
H
L
3

1
1
M
,
3
0
2
4
0
8
V
M
,
FM
R

2

2
2
M
P
,
IA
M
M
F

1
V
M
+
n
.d
.
R

3

1
2
F,
2
4
1
0
0
3
0
FM
L

1

2
2
IV
IG
,
M
P
M
P

2
0
FM
+
+
R
L

3

1
3
F,
2
4
5
1
5
0
V
M
,
FM
L

0

2
7
M
P
,
IA
C
y
c,
A
za
,
M
M
F
L
2
n
.d
.
n
.d
.
+
S
A
H
L

2

M
e
d
ia
n
s
(r
a
n
g
e
)
2
4
(8
–
4
7
)
1
8
(1
–
2
5
2
)
1
0
(1
–
1
5
0
)
1 (0
–
3
)
3
7
(1
2
–
8
4
)
2
(1
–
4
)
5
(0
–
6
0
)
2 (2
–
4
)
M
o
,
m
o
n
th
;
sz
,
se
iz
u
re
;
A
E
D
,
a
n
ti
e
p
il
e
p
ti
c
d
ru
g
s;
V
M
,
v
e
rb
a
l
m
e
m
o
ry
;
FM
,
ﬁ
g
u
ra
l
m
e
m
o
ry
;
R
,
ri
g
h
t;
L,
le
ft
;
FU
,
fo
ll
o
w
-u
p
;
IT
,
im
m
u
n
o
tr
e
a
tm
e
n
t;
M
P
,
m
e
th
y
lp
re
d
n
is
o
lo
n
e
,
IV
IG
,
i.
v
.
im
m
u
n
o
g
lo
b
u
li
n
e
s;
P
E
X
,
p
la
sm
a
p
h
e
re
si
s;
IA
,
im
m
u
n
o
a
d
so
rp
ti
o
n
;
S
A
H
,s
e
le
ct
iv
e
a
m
y
g
d
a
lo
-h
ip
p
o
ca
m
p
e
ct
o
m
y
;
M
M
F,
m
y
co
p
h
e
n
y
la
t-
m
o
fe
ti
l;
A
za
,a
za
th
io
p
ri
n
;
C
y
c,
cy
cl
o
p
h
o
sp
h
a
m
id
;
N
a
ta
,N
a
ta
li
zu
m
a
b
;
ID
D
M
,i
n
su
li
n
d
e
p
e
n
d
e
n
t
d
ia
b
e
te
s
m
e
ll
it
u
s;
S
LS
,s
ti
ff
li
m
b
sy
n
d
ro
m
e
.
a
Li
st
e
d
in
ch
ro
n
o
lo
g
ic
a
l
se
q
u
e
n
ce
.
13
12
11
10
9
8
7
6
5
4
3
2
1
SAH
Steroids (g)
IVIG (g/kg BW)
PEX 
IA 
Natali zumab (g) 
1 2 3 4 5
20
3
15
2
13,5
25
3,6
30
15
18,5
7,5
22,4
1
1
1
2,8
2
3
2
21
2
2,4 1 1
1 1,2
1
2
P
at
ie
nt
s
The rap ies
Fig. 1. Immunotherapies in chronological sequence in individual GAD-TLE patients.
SAH, selective amygdalo-hippocampectomy; IVIG, intravenous immunoglobulines;
PEX, plasmapheresis; IA, immunoabsorption; Nata, natalizumab; BW, body weight.
M.P. Malter et al. / Seizure 30 (2015) 57–6360number of sequences: 1, range 1–2), always in conjunction with
immunosuppression in form of oral prednisolone and/or cyclo-
phosphamide or mycophenolate mofetil. Half of the patients
underwent immunoadsorption combined with CSF drainage
(N = 4). This was not superior in seizure frequency reduction.
Among the eight patients with immunoadsorption, one was a
responder (13%). Memory parameters did not reveal group effects
(t-test: n.s.). On individual levels, VM and FM deteriorated each in
one patient, FM improved in one patient. Median changes of GAD-
abs were 75% in serum (100% to 50%, N = 7) and 25% in CSF
(75% to +56%, N = 8). All patients with CSF drainage refused a
second cycle because of dorsal pain or feeling uncomfortable with
this therapy. No further relevant adverse events were seen during
immunoadsorption.
3.2.1.4. Natalizumab (N = 1). One patient was treated with 1.2 g
natalizumab for three months with good seizure response but
without memory changes. GAD-ab titres were not available.
Despite seizure response without adverse events, treatment was
discontinued because of new insights in the meantime regarding
elevated risk for progressive multifocal leukencephalopathy (PML)
in patients with previously received immunosuppressants [28].
3.3. Epilepsy surgery (N = 3)
Three patients underwent selective amygdalo-hippocampect-
omy because of medically intractable seizures. In only one of these,
diagnosis of GAD-TLE was known at the time of decision for
surgery. In the other two patients, surgery was performed prior to
visit 1. Routine histopathological evaluation of two surgical
specimens revealed lymphocytic T-cell inﬁltration compatible
with chronic encephalitis. These patients had a relevant seizure
frequency reduction after surgery, but achieved no seizure
freedom (Engel IIA). The third patient with normal histopathology
was the one with the maximum disease duration of 10.6 years at
time of surgery and was not treated with immunosuppressants
after surgery. She had no improvement in seizure control after
surgery.
3.4. AEDs only (N = 7)
One of these seven patients (14%) had not just seizure frequency
reduction 50% but was even seizure free for 17 months at last
M.P. Malter et al. / Seizure 30 (2015) 57–63 61follow up with persistently positive GAD-ab titres (Engel IA). On
the other hand, two patients deteriorated in seizure frequency
after discontinuation of immunotherapy. One of them had been
operated before (No. 1) with encephalitic histopathology. Subse-
quently to termination of oral steroids 20 months after operation
(Engel IIA), encephalitis relapsed in contralateral mediotemporal
structures. The patient recovered after re-initiation of several
immunotherapies but did not regain previous outcome level (Case
vignette in Ref. [29]).
3.5. Last follow up
For individual outcomes, see Table 1. At last available follow
up (median: 34 months, range 6–84) after a median of two
immunological interventions (range 1–4) and three epilepsy
surgery procedures, 10 patients (91%) had 50% seizure frequency
reduction as compared to visit 1, but only one patient (8%) was
seizure-free for at least 12 months (patient No. 4). He was on AEDs
only after discontinuation of immunotherapy.
Memory outcome data at last follow up were available in 12/13
patients. Individual changes from pathological to normal memory
performance were only seen in ﬁve patients for FM. No group
effects were observed comparing VM and FM at visit 1 and follow
up (t-test: visit1 vs. follow up).
Among the available materials, only one serum became GAD-
ab-negative.
MRI was available in 12 patients at last available follow up: in
three patients (25%) mediotemporal encephalitic MRI features
had evolved from unilateral to bilateral. In two, MRI abnormali-
ties had regressed from bilateral to unilateral. The remaining
seven patients were unchanged. None of the patients developed
hippocampal atrophy during the follow up period.
Insulin dependent diabetes mellitus and stiff-person-syndrome
newly occurred as GAD ab associated comorbidities in one patient
during follow up period. None of the patients had a tumour
detected.
4. Discussion
In GAD-TLE we observed a poor responsiveness of seizures to
several immunotherapies and epilepsy surgery as add-on inter-
ventions to standard AED therapy. Only one out of 13 patients
achieved seizure freedom for 12 months at last follow-up.
Seizure response (50% reduction) was most frequently achieved
under corticosteroids (45% of patients) with no apparent or
beneﬁcial effects on memory function. However, relevant side
effects were observed in 50% of the patients. IVIG were less
effective in seizure response (20%) but with better tolerability than
corticosteroids. Clinical beneﬁt under apheresis therapies was
poor. Natalizumab was helpful in the one treated case, but
treatment (and response) could not be maintained due to
discontinuation of the therapy because of concern about PML.
Memory outcome, too, was not signiﬁcantly affected by any
treatment regimen. GAD-ab titres declined but did mostly not
become negative. This suggests an enduring synthesis of GAD-abs.
Serial MR imaging suggests continuous, in part spreading, disease
activity, however no destructive course.
A number of previous case reports or small patient series on
therapy outcome of GAD-TLE using immunotherapy produced
inconsistent results [3,4,30–35]. In a recently published study
regarding seizure outcome of patients with autoimmune epilep-
sies, four GAD-TLE patients were included: two of them had a
favourable outcome under immunotherapy with IVIG and MP
gaining seizure-freedom for a period of 6–18 months [36]. Lilleker
et al. [33] reported poor response on MP (N = 4) and IVIG (N = 1) in
ﬁve patients with GAD-TLE.Our poor therapeutic results even with strongly ab reducing
measures such as apheresis challenge the direct pathogenicity of
GAD-abs, which is still matter of debate [3,37–39]. There is
evidence from in vivo studies of direct effects of GAD-ab containing
biomaterials on neuronal tissues and in experimental animals
[10,40]. A recent study showed reduced cortical GABA levels in
MRI-spectroscopy in patients with GAD-TLE. The authors could,
however, not determine whether their effects were due to a direct
involvement of GAD-abs in pathogenesis or only epiphenomena of
underlying unknown processes. They concluded that a clear
response to immunotherapy would help to solve this particular
question [41]. A major argument against direct involvement in
pathological processes is the intracellular location of GAD with
poor accessibility for abs. Recent ﬁndings on immunopathology of
ab-associated encephalitides with three patients with GAD-TLE
included support the hypothesis of a T-cell mediated immunopa-
thology in these patients rather than humoral immune response
[12]. The poor effect of apheresis therapies with priority on ab
elimination in our study strengthens the assumption that these abs
are not directly pathogenic.
According to histopathological ﬁndings [12], natalizumab was
used as a promising new approach to block T-cell entry into the
CNS. Although we observed encouraging therapy results in one
patient, it has to be mentioned that the updated risk warnings for
PML in patients with previous immunotherapy [28] are a hurdle for
long-term off-label use in GAD-TLE patients at the moment. Future
attempts with other biologicals directed to T-cells may overcome
this. One option might be rituximab, which is now increasingly
used in neurology and has an indirect inhibiting effect on
pathogenic T-cells [38].
However, it should also be taken into account that extensive
immunotherapies can cause severe side effects and their particular
high costs, especially that of immunoadsorption and the newer
immunosuppressants, put a strain on public health care systems.
Hence, their use should be considered reasonably. Best therapeutic
response in our cohort was achieved with corticosteroids, which
are low-priced but have, on the other hand, severe side effects on
long-term use.
Experiences in epilepsy surgery in GAD-TLE are rare and the
small number of operated patients in our study group does not
allow general conclusions but some interesting observations have
to be emphasized. Two of the three operated GAD-TLE patients had
relevant seizure frequency reduction under subsequent supportive
immunosuppressive therapy but none of them remained seizure
free after surgery. On the other hand, one operated patient
experienced inﬂammatory relapse in contralateral mediotemporal
structures after discontinuation of immunosuppressive therapy
and did not regain previous cognitive level and seizure freedom
after re-initiation of immunotherapy. The lack of seizure-free
patients after surgery and extensions of encephalitic MRI features
to the contralateral mediotemporal structures reﬂect the chronic
and potentially progressive nature of this condition. Again, the fact
that none of the patients newly developed hippocampal atrophy
reﬂects a mild destructive potential. According to these ﬁndings,
identiﬁcation of GAD-TLE prior to surgery could be relevant for
outcome prediction.
The fact that one patient newly developed insulin dependent
diabetes mellitus and stiff-person-syndrome during follow up
period raised the question wether the syndrome of GAD-TLE
reﬂects only an aspect of a more generalized or multifocal GAD-ab-
associated autoimmune syndrome. Consecutive long-term follow
up of the patients could uncover such mechanisms.
There are, of course, relevant limitations to our study. We only
considered patients from a tertiary epilepsy centre with chronic
epilepsies. Our data are thus presumably biased towards more
chronic and difﬁcult-to-treat epilepsies. It cannot be excluded that
M.P. Malter et al. / Seizure 30 (2015) 57–6362the patients harboured other abs in addition to GAD65 abs. This
has been observed e.g. in Anti-GABAB receptor encephalitis
[42,43]. However, overlaps seem not to be so frequent and do
not necessarily mean that the prognosis is different (as has been
reported with GAD-ab associated cerebellar ataxia and abs to the
glycine receptor [44]). The patient group is larger than in most
existing series, the numbers are, however, still small. Inclusion
period ends in 2010, therefore we cannot exclude that newer
treatment approaches could be more promising, although we are
not aware of new systematic therapeutic efforts on this topic. Most
patients received several interventions at different time points.
Therefore, the evaluation of the individual therapies could not be
done chronologically and the outcome variables are not indepen-
dent. AED treatment was conducted in all patients, changes in
medication occurred and inﬂuences on outcome cannot be
excluded (however, it is likely that a more restricted handling of
the AEDs would not have improved seizure outcome). Taken
together, our data cannot go beyond a descriptive level. For further
exploration and to share experience of this rare syndrome, a
multicentric database could be helpful.
Despite these limitations, this is the ﬁrst study which attempts
to summarize the effect of various therapeutic interventions in a
medium-sized sample of GAD-TLE patients. There were no
resounding successes as are often observed with limbic encepha-
litis with abs against surface antigens. GAD-TLE seems to take a
chronic course, resistant mostly to AED, immunotherapy and
epilepsy surgery.
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